

### **GENERAL CANCER TRIALS**

**A222004**, “A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia,” (ClinicalTrials.gov NCT04939090)

### **BREAST CANCER**

**NRG - BR003**: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (ClinicalTrials.gov NCT #02488967)

**GCC-1366**: A Prospective Study of Neoadjuvant Non-steroidal Aromatase Inhibitors in Postmenopausal Women with Operable Hormone Receptor-Positive Breast Cancer to Evaluate the Anti-proliferative Response in Obese and Overweight Patients (ClinicalTrials.gov NCT# 02095184)

**S1501**: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III (ClinicalTrials.gov NCT#03418961)

**A191901**: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (ClinicalTrials.gov NCT#04379570)

**A011801**: “The CompassHER2 trials (COMprehensive use of Pathologic Response ASSESSment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib” (ClinicalTrials.gov NCT #04457596)

### **HEAD / NECK CANCER**

**EA3161**: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive head and neck cancer (ClinicalTrials.gov NCT# 03811015)

### **GYNECOLOGICAL CANCER**

**NRG GY 018**: Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (ClinicalTrials.gov NCT # 03914612 )

### **COLORECTAL CANCER**

**S0820: PACES** - A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III

Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac  
(ClinicalTrials.gov NCT# 01349881)

**A221805:** Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II To Phase III Study (ClinicalTrials.gov NCT#04137107)

**NRG-GI005:** Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA) ( ClinicalTrials.gov NCT #04068103)

**NRG-GI008,** Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NCT 05174169)

### **LUNG CANCER**

**LUNGMAP:** A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (ClinicalTrials.gov NCT # 03851445)

**A151216-**(Screening Trial) ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ClinicalTrials.gov NCT# 02194738 )

**E4512-**(ALCHEMIST Treatment Trial): A Randomized Phase III Trial for Surgically Resected Early Stage Non Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the AnaplasticLymphoma Kinase (ALK) Fusion Protein (ClinicalTrials.gov NCT# 02201992)

**A081801-** (treatment trial): ALCHEMIST chemo-IO (ACCIO): Integration of immunotherapy into adjuvant therapy for resected NSCLC (ClinicalTrials.gov NCT# 04267848 )

**EA5181:** Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (ClinicalTrials.gov NCT# 04092283 )

### **BLOOD and LYMPHATIC SYSTEM DISORDERS**

**NHLBI-MDS:** The National Myelodysplastic Syndromes Natural History Study (ClinicalTrials.gov NCT # 02775383)

**S1826:** A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma ( ClinicalTrials.gov NCT # 03907488)

### **REPOSITORY: MULTI-SITE TISSUE and BIOFLUID BANKING**

**AST-FPB-US :** A Multi-Center Study for the Collection of Surplus Surgical Tissues for Genomics, Proteomics and Biomarker Research (Fresh, Preserved, Biofluid

**MTG-015:** Tissue and Bodily Fluids. Discovery and Evaluation of Biomarkers for the Diagnosis and Treatment of Disease

**QUALITY OF LIFE STUDIES**

**MARYLAND LIVING WELL, CANCER: THRIVING AND SURVIVING QOL RESEARCH:** Maryland Department on Aging, Maryland Department of Health and Mental Hygiene